ClinicalTrials.gg
RecruitingNCT05380765Updated Jun 5, 2024

Developing a Positive Approach to Substance Use Prevention in North American Indian Adolescents

An interventional study of Native PATHS in Alcohol Drinking, Tobacco Use and Drug Use, sponsored by University of Rhode Island. Recruiting at 1 site in United States. Open to participants aged 10 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-05.

Primary conditionTobacco UseRegistry: Alcohol DrinkingReclassifiedWhy we changed it
Registry
Alcohol Drinking — the first condition term the registry derived for this study.
ClinicalTrials.gg
Tobacco Use
Why
  1. Alcohol Drinking is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Tobacco Use.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Rhode Island · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
10 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 313 studies in Tobacco Use with a site in United States — 54 open to participants now, 65 under way, 1 of them phase 3. Tobacco Use · United States.

Planned enrollment
195th of 288
60 · median 120
Started
2024
with 21 others
No phase
233 of 313
40 open now
Primary completion
2025-05
later than 2 of 64 live
Registered
216th of 313
by date

Among the 313 studies in Tobacco Use with a site in United States, this one is the 195th largest by planned enrollment of the 288 interventional ones that give a count, is one of 22 that started in 2024, is one of 233 with no phase, reaches primary completion later than 2 of the 64 other live ones, and was the 216th registered.

Tobacco Use

423 studies on the registry are indexed under Tobacco Use; 85 are open to participants now.

Browse Tobacco Use studies →

Open to participants now

54 of the 313 studies in Tobacco Use with a site in United States are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Tobacco Use studies recruiting now, 28 (55%) set no upper age limit and 19 (37%) stop at 75 or younger; 2 take children under 18; 28 take healthy volunteers.

This study: 10 Years to 14 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Tobacco Use with a site in United States, or all of them as a file.
02

Study summary

The overall objective of this project is to develop and obtain preliminary data on acceptability, feasibility, and initial efficacy of Native PATHS. This work is guided by the stage model guidelines for treatment development and adaptation 25. Stage 1a will occur in two sequential steps. First, the investigators will recruit youth who are in 5th - 8th grade and their family members (N=24, 12 youth, 12 adults 18+) to participate in three talking circle sessions to obtain feedback on the cultural adaptation and implementation of the treatment. Next, the investigators will conduct an open label pilot (N=9). Youth and their family members, (up to 3 per youth) will provide qualitative and quantitative feedback after each session. In Stage 1b, 60 youth will participate in a pilot randomized controlled trial, testing the efficacy of the newly created program (n=30) against a wait list control (WLC) condition (n=30). Ultimately, this program of research is expected to result in a well-specified, efficacious prevention program that could be readily disseminated and generalizable to other Indigenous populations with minimal adaptation.

Read the detailed description

Alcohol is one of the primary determinants of health disparity among many Indigenous populations with rates of alcohol-attributable mortality substantially higher than for Whites (73.8 per 100,000 vs. 27.5), and therefore, is a key threat to optimal health and well-being to Indigenous youth. Indigenous youth living in both the US and Canada tend to begin using alcohol, tobacco, and other drugs (ATOD) at earlier ages than most other ethnic/racial groups, and tend to move more quickly to regular use, resulting in earlier onset of ATOD disorders. Despite the severity of the problem, there continues to be an urgent unmet need for effective prevention programs that are culturally tailored to Indigenous populations of the US and Canada. The overall objective of this project is to develop and obtain preliminary data on the acceptability, feasibility, and initial efficacy of Native PATHS (Positive Approaches to reducing Harm from Substance Use). Native PATHS is a strengths-based, family prevention program for Indigenous youth in 5th-8th grade which focuses on delayed ATOD initiation. The development of Native PATHS has been guided by formative work in this community, taking a behavioral economic and positive psychological approach to prevention. Applied to prevention, behavioral economic theory focuses on reducing the availability of ATOD and increasing ATOD-free alternatives and the reinforcement received from engaging in ATOD-free activities. Activities in Native PATHS will work with families to help with establishing ATOD-free rules, limit physical availability of ATOD in the home, and reinforce youths' participation in ATOD-free activities. Positive psychological interventions (PPIs) focus on increasing positive emotions, life satisfaction, and well-being. PPIs will be used to enhance the enjoyment received from ATOD-free activities and to improve life satisfaction. Native PATHS is culturally consistent with North American Indigenous views of health that describe health in terms of a balance between the physical, spiritual, emotional, and mental aspects of life, which is represented in the teachings of the Medicine Wheel. Collaboratively, the investigators will work together with tribal partners on further adaptation of the program to include family and Indigenous ways of parenting in a culturally meaningful way. The overall goals proposed project will 1) finalize Native PATHS with participation from youth and family members in talking circles and an open pilot trial; 2) assess the effectiveness of Native PATHS in reducing ATOD initiation and intentions to use ATOD; 3) begin to evaluate the possible mechanisms/moderators of action including potential mediators future orientation and alternative reinforcer/activity engagement and reinforcement received, compared to a wait-list control group. The investigators will also evaluate positive affect as a potential moderator of any treatment effect, such that those higher in positive affect will be less likely to engage in ATOD use and be less likely to endorse intentions to use ATOD.

03

Conditions studied

  • Alcohol Drinking
  • Tobacco Use
  • Drug Use

Browse trials for

04

In context

Tobacco Use Reclassified

423 studies on the registry are indexed under Tobacco Use; 85 are open to participants now.

This study's planned enrollment of 60 is below the median of 131 across 354 interventional studies indexed under Tobacco Use.

Browse Tobacco Use studies →

Lead sponsor

University of Rhode Island is the lead sponsor of 34 studies on the registry; 5 are open to participants now.

Compared within Tobacco Use, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Alcohol Drinking. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
10 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria - Youth Participants:

  1. residing in the First Nation community,
  2. identify as a member of a First Nation,
  3. be in grades 5th - 8th at time of enrollment, and
  4. one youth per household may participate.

Inclusion Criteria - Family Participants:

  1. at least 18 years of age
  2. reside within the First Nation community
  3. be identified, by the youth, as an important influence in their life
  4. be committed to helping the youth make good decisions regarding using substances
06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Native PATHS Condition

    A strengths-based, behavioral economic approach to increasing engagement and reinforcement for engaging in alternative activities.

    Behavioral: Native PATHS

  • No intervention
    Wait-List Control

    Participants will receive the Native PATHS program once 6-month follow up surveys have been completed.

Interventions

  • BehavioralNative PATHS

    A strengths-based, behavioral economic approach to increasing engagement and reinforcement for engaging in alternative activities.

07

What researchers measure

Primary outcomes

  1. Past month alcohol use

    Respondents will be asked whether they have used alcohol in the past month (yes/no).

    Time frame: Baseline

  2. Past month alcohol use

    Respondents will be asked whether they have used alcohol in the past month (yes/no).

    Time frame: End of treatment (up to 12 weeks following baseline)

  3. Past month alcohol use

    Respondents will be asked whether they have used alcohol in the past month (yes/no).

    Time frame: Six months following end of treatment

  4. Past three-month alcohol use

    Respondents will be asked whether they have used alcohol in the past three months (yes/no).

    Time frame: Baseline

  5. Past three-month alcohol use

    Respondents will be asked whether they have used alcohol in the past three months (yes/no).

    Time frame: End of treatment (up to 12 weeks following baseline)

  6. Past three-month alcohol use

    Respondents will be asked whether they have used alcohol in the past three months (yes/no).

    Time frame: Six months following end of treatment

  7. Past month marijuana use

    Respondents will be asked whether they have used marijuana in the past month (yes/no).

    Time frame: Baseline

  8. Past month marijuana use

    Respondents will be asked whether they have used marijuana in the past month (yes/no).

    Time frame: End of treatment (up to 12 weeks following baseline)

  9. Past month marijuana use

    Respondents will be asked whether they have used marijuana in the past month (yes/no).

    Time frame: Six months following end of treatment

  10. Past three-month marijuana use

    Respondents will be asked whether they have used marijuana in the past three months (yes/no).

    Time frame: Baseline

  11. Past three-month marijuana use

    Respondents will be asked whether they have used marijuana in the past three months (yes/no).

    Time frame: End of treatment (up to 12 weeks following baseline)

  12. Past three-month marijuana use

    Respondents will be asked whether they have used marijuana in the past three months (yes/no).

    Time frame: Six months following end of treatment

  13. Past month cigarette smoking

    Respondents will be asked whether they have smoked cigarettes in the past month (yes/no).

    Time frame: Baseline

  14. Past month cigarette smoking

    Respondents will be asked whether they have smoked cigarettes in the past month (yes/no).

    Time frame: End of treatment (up to 12 weeks following baseline)

  15. Past month cigarette smoking

    Respondents will be asked whether they have smoked cigarettes in the past month (yes/no).

    Time frame: Six months following end of treatment

  16. Past three-month cigarette smoking

    Respondents will be asked whether they have smoked cigarettes in the past three months (yes/no).

    Time frame: Baseline

  17. Past three-month cigarette smoking

    Respondents will be asked whether they have smoked cigarettes in the past three months (yes/no).

    Time frame: End of treatment (up to 12 weeks following baseline)

  18. Past three-month cigarette smoking

    Respondents will be asked whether they have smoked cigarettes in the past three months (yes/no).

    Time frame: Six months following end of treatment

  19. Alcohol use intentions

    Respondent will be asked how often in the next month they think they will get drunk with friends and how often in the next month they would like to get drunk with friends, on a five-point scale from 0 (never) to 4 (10 or more times), where higher scores indicate more frequent intentions to use alcohol in the next month.

    Time frame: Baseline

  20. Alcohol use intentions

    Respondent will be asked how often in the next month they think they will get drunk with friends and how often in the next month they would like to get drunk with friends, on a five-point scale from 0 (never) to 4 (10 or more times), where higher scores indicate more frequent intentions to use alcohol in the next month.

    Time frame: End of treatment (up to 12 weeks following baseline)

  21. Alcohol use intentions

    Respondent will be asked how often in the next month they think they will get drunk with friends and how often in the next month they would like to get drunk with friends, on a five-point scale from 0 (never) to 4 (10 or more times), where higher scores indicate more frequent intentions to use alcohol in the next month.

    Time frame: Six months following end of treatment

  22. Cigarette smoking susceptibility

    Cigarette smoking intentions will be measured using the Susceptibility to Smoking measure, which includes four items that asking respondents the likelihood that they will begin to smoke/experiment with cigarettes on a four-point scale from 0 (definitely not) to 3 (definitely yes), with higher scores indicating greater likelihood of intending to smoke cigarettes in the future.

    Time frame: Baseline

  23. Cigarette smoking susceptibility

    Cigarette smoking intentions will be measured using the Susceptibility to Smoking measure, which includes four items that asking respondents the likelihood that they will begin to smoke/experiment with cigarettes on a four-point scale from 0 (definitely not) to 3 (definitely yes), with higher scores indicating greater likelihood of intending to smoke cigarettes in the future.

    Time frame: End of treatment (up to 12 weeks following baseline)

  24. Cigarette smoking susceptibility

    Cigarette smoking intentions will be measured using the Susceptibility to Smoking measure, which includes four items that asking respondents the likelihood that they will begin to smoke/experiment with cigarettes on a four-point scale from 0 (definitely not) to 3 (definitely yes), with higher scores indicating greater likelihood of intending to smoke cigarettes in the future.

    Time frame: Six months following end of treatment

  25. Marijuana use intentions

    Respondent will be asked how often in the next month they think they will use marijuana with friends and how often in the next month they would like to use marijuana with friends, on a five-point scale from 0 (never) to 4 (10 or more times), where higher scores indicate more frequent intentions to use marijuana in the next month.

    Time frame: Baseline

  26. Marijuana use intentions

    Respondent will be asked how often in the next month they think they will use marijuana with friends and how often in the next month they would like to use marijuana with friends, on a five-point scale from 0 (never) to 4 (10 or more times), where higher scores indicate more frequent intentions to use marijuana in the next month.

    Time frame: End of treatment (up to 12 weeks following baseline)

  27. Marijuana use intentions

    Respondent will be asked how often in the next month they think they will use marijuana with friends and how often in the next month they would like to use marijuana with friends, on a five-point scale from 0 (never) to 4 (10 or more times), where higher scores indicate more frequent intentions to use marijuana in the next month.

    Time frame: Six months following end of treatment

08

Study locations

1 of 1 sites recruiting
  • University of Rhode Island
    Kingston, Rhode Island 02881-1967, United States
    Recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2024; primary completion for May 2025, 11 months later.

Of 167 non-industry interventional studies with no phase under Tobacco Use, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 11 months is below that.

Counting every sponsor, half of 224 studies reached it within 16 months; a quarter within 5 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2022
First posted
May 19, 2022
StartEst.
Jun 17, 2024
Primary completionEst.
May 31, 2025
CompletionEst.
May 31, 2025
Last update
Jun 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05380765
Lead sponsor
University of Rhode Island
Responsible party
Sponsor
First posted
May 19, 2022
Start date
Jun 17, 2024 (estimated)
Primary completion
May 31, 2025 (estimated)
Completion
May 31, 2025 (estimated)
Last update
Jun 5, 2024

Study contacts

Nichea S Spillane, Ph.D.
Contact
nspillane@uri.edu
(401) 874-4252
Nichea S Spillane, Ph.D.
principal investigator · University of Rhode Island

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion